Immunotherapy and Systemic Treatment of Cutaneous Squamous Cell Carcinoma

Cutaneous squamous cell carcinomas (cSCC) represent one of the most diagnosed non-melanoma skin cancers and its incidence is increasing globally. Whereas early stage and low risk cSCC is typically treated with surgery, and in some cases other localized therapeutic modalities, locally advanced or met...

Full description

Saved in:
Bibliographic Details
Published in:Dermatology practical & conceptual 2021-11, Vol.11 (Suppl 2), p.e2021169S-e2021169S
Main Authors: Aboul-Fettouh, Nader, Morse, Daniel, Patel, Jigar, Migden, Michael R
Format: Article
Language:English
Subjects:
advanced cSCC
cSCC
cutaneous squamous cell carcinoma
immunotherapy
Review
systemic therapies
tumor response
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cutaneous squamous cell carcinomas (cSCC) represent one of the most diagnosed non-melanoma skin cancers and its incidence is increasing globally. Whereas early stage and low risk cSCC is typically treated with surgery, and in some cases other localized therapeutic modalities, locally advanced or metastatic cSCC is a cause of significant morbidity and mortality that requires a different approach to therapy. Therapeutic attempts at treating advanced cSCC include a multi-disciplinary approach with considerations for surgery, radiation, and systemic therapies. In this review, we will discuss the various systemic therapies that have been trialed for advanced cSCC, beginning with the early cytotoxic and platinum-based agents as well as their corresponding limitations. We will then review the targeted approaches using EGFR inhibitors prior to discussing the more recent immunotherapeutics that have shown good tumor responses in this often-lethal disease.
ISSN:2160-9381
2160-9381
DOI:10.5826/dpc.11S2a169S